Skip to Main Content

Advertisement

American Association for Cancer Research Logo Open Menu
American Association for Cancer Research Logo Close
  • AACR Journals Open Menu
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Cancer Research Communications
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics
  • For Authors Open Menu
    • Information for Authors
    • Author Services
    • Journal Awards
  • About Us Open Menu
    • AACR Journals
    • Advertising
    • Permissions & Reprints
    • Subscriptions
    • Submit
  • Article Collections Open Menu
    • Cancer Hallmarks Collection
    • Hot Topics
    • Towards Degrader-Antibody Conjugates
    • Advances in Tumor Immunology and Immunotherapy
    • Editors' Picks
    • COVID-19
  • Alerts
  • News
  • Cancer Hallmarks
  • Webinars
Search Dropdown Menu
header search
    Search
    Advanced Search
    User Tools Dropdown
    Register
    Sign In Open Menu
    Molecular Cancer Therapeutics
    Toggle MenuMenu
    • AboutOpen Menu
      • The Journal
      • Editorial Board
      • AACR Journals
      • Subscriptions
      • Permissions and Reprints
    • ArticlesOpen Menu
      • Online First
      • Issues
      • Meeting Abstracts
      • Collection: Editors' Picks
      • COVID-19
    • First Disclosures
    • For AuthorsOpen Menu
      • Information for Authors
      • Author Services
      • Outstanding Journal Article Award
      • SubmitOpen External Link
    • Alerts
    • News
    • Cancer Hallmarks
    • Webinars
    Skip Nav Destination

    Update search

    Querybuilder input 1
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 2
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 3
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 4
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 5
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References
    Querybuilder input 6
    Filter All
    • All
    • Title
    • Author
    • Author Affiliations
    • Full Text
    • Abstract
    • Keyword
    • DOI
    • ISSN
    • EISSN
    • Issue
    • Volume
    • References

    NARROW

    Format

    Filter by format

    Subjects

    Filter by subjects

    Journal

    Filter by journal

    Article Type

    Filter by article-type

    Issue Section

    Filter by issue-section

    Date

    Filter by date
    Apply

    Availability

    Availability
    1-1 of 1
    Yaoyu Ning
    Close
    Save search
    Follow your search
    Access your saved searches in your account
    Would you like to receive an alert when new items match your search?
    Close Modal
    Sort by
    Journal Articles

    Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

    Free
    Victor M. Rivera, Rachel M. Squillace, David Miller, Lori Berk, Scott D. Wardwell, Yaoyu Ning, Roy Pollock, Narayana I. Narasimhan, John D. Iuliucci, Frank Wang, Tim Clackson
    Journal: Molecular Cancer Therapeutics
    Mol Cancer Ther (2011) 10 (6): 1059–1071.
    https://doi.org/10.1158/1535-7163.MCT-10-0792
    Published: 08 June 2011
    Abstract
    View articletitled, Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
    Open the PDF for Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens in another window
    Includes: Supplementary data

    Advertisement

    Email alerts

    Online First Alert
    eTOC Alert
    Close Modal
    • Online ISSN 1538-8514
    • Print ISSN 1535-7163

    AACR Journals

    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Cancer Research Communications
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

     

     

    • Information on Advertising & Reprints
    • Information for Institutions/Librarians
    • RSS Feeds
    • Privacy Policy
    • Twitter
    • LinkedIn
    • Facebook
    • Youtube
    • Copyright © 2025 by the American Association for Cancer Research.
    Close Modal
    Close Modal
    This Feature Is Available To Subscribers Only

    Sign In or Create an Account

    Close Modal
    Close Modal
    This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
    Accept